KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teladoc Health (TDOC) Other financing activities (2016 - 2025)

Teladoc Health's Other financing activities history spans 10 years, with the latest figure at -$1000.0 for Q4 2025.

  • For Q4 2025, Other financing activities changed N/A year-over-year to -$1000.0; the TTM value through Dec 2025 reached $4.1 million, changed N/A, while the annual FY2025 figure was $4.1 million, N/A changed from the prior year.
  • Other financing activities for Q4 2025 was -$1000.0 at Teladoc Health, down from $4.1 million in the prior quarter.
  • Across five years, Other financing activities topped out at $5.3 million in Q2 2021 and bottomed at -$9.4 million in Q3 2021.
  • The 5-year median for Other financing activities is -$23000.0 (2024), against an average of -$419058.8.
  • The largest annual shift saw Other financing activities plummeted 1431.02% in 2022 before it surged 5172.84% in 2025.
  • A 5-year view of Other financing activities shows it stood at -$842000.0 in 2021, then surged by 292.64% to $1.6 million in 2022, then crashed by 277.99% to -$2.9 million in 2023, then surged by 97.19% to -$81000.0 in 2024, then surged by 98.77% to -$1000.0 in 2025.
  • Per Business Quant, the three most recent readings for TDOC's Other financing activities are -$1000.0 (Q4 2025), $4.1 million (Q3 2025), and -$81000.0 (Q3 2024).